Abstract
Pitavastatin is a synthetic 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, which was approved for the primary treatment of hypercholesterolemia and combined dyslipidemia since 2009. Today, in vitro and in vivo studies have shown pitavastatin as a potentially effective therapeutic agent for different cancers, including; liver, ovarian, breast, skin, and intestinal cancers. These studies have evaluated pitavastatin both as a single treatment and in combination with other therapeutic options. This chapter focuses on the potential anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use.
Keywords: Anti-cancer, Anti-inflammatory, Apoptosis, Autophagy, Cell cycle arrest, Pitavastatin.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Current Radiopharmaceuticals
Recent Patents on Anti-Cancer Drug Discovery
Current Medicinal Chemistry - Anti-Cancer Agents
Current Cancer Therapy Reviews
Clinical Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents